Drug profile · INN
betamethasone benzoate
UTICORT
betamethasone benzoate (UTICORT) is a glucocorticoid receptor agonist. Route of administration: topical. Current US regulatory status: approved.
Drug details — betamethasone benzoate
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
betamethasone benzoate (UTICORT) is a glucocorticoid receptor agonist. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is betamethasone benzoate?
betamethasone benzoate (UTICORT) is a glucocorticoid receptor agonist. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for betamethasone benzoate?
UTICORT is a marketed brand name for betamethasone benzoate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of betamethasone benzoate?
betamethasone benzoate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.